The collaboration is part of VitaDAO’s latest fundraising disclosed in late January from strategic members, including Pfizer Ventures, Shine Capital and L1 Digital, among other longevity enthusiasts. The $4.1 million raised will be used to fund longevity research projects and accelerate the spinout of VitaDAO’s first biotech startups, with two more in development for 2023.
“Pfizer is now bringing some of their own scientists to join with the community of researchers who are part of VitaDAO to help incubate some of this research,” told Cointelegraph Alex Dobrin, community and awareness steward at VitaDAO.
DeSci has fostered the emergence of a thriving ecosystem with projects ranging from decentralized biotech foundations to funding vehicles. “Some of the major trends in the field can include research & investment platforms, crowdfunding for scientific research, scientists and researcher communities,” explained Dr. Tuan Cao, founder of GenomicDAO, a San Francisco-based platform launched on Feb. 19 by AI biotech company Genetica.
This decentralized platform aims to establish a community to drive and govern Asian-focused precision medicine initiatives. Its first subsidiary DAO is working on stroke prevention, targeting awareness and R&D for ischemic strokes.
Worldwide, stroke is one of the most common causes of disability and vascular death. The American Heart Association reports that there were over 77 million ischemic strokes around the world in 2019. Asian populations have higher stroke incidences than Western populations, according to a study published in the Journal of clinical hypertension in 2021.
GenomicDAO claims that the combination of a network of research groups, institutions, organizations, scientists and medical experts with artificial intelligence can reduce time to release a new product from 12–18 months to 4–6 months. According to GenomicDAO, community-driven initiatives are disrupting scientific research:
“In the precision medicine space, R&D is led by a handful of big names in the industry that are de-facto monopolizing the market. Monopolistic and centralized pharmaceutical companies equivalently lead to the stagnation of innovation; simultaneously widening the gap in providing precision medicine to underrepresented populations.”
(adsbygoogle = window.adsbygoogle || ).push();